...
首页> 外文期刊>British Journal of Cancer >'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease
【24h】

'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease

机译:“肝癌特异性”甲胎蛋白可能允许对慢性肝病患者进行恶性改变的临床前诊断

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The only hope for effective treatment of hepatocellular carcinoma (HCC or 'hepatoma') lies in early diagnosis. Measurement of the serum alphafetoprotein (AFP) level is potentially a useful screening test. When grossly raised, it is almost diagnostic of HCC. However, modestly elevated levels may also arise in patients with benign chronic liver disease, and this markedly decreases the test's specificity and hence its clinical value. In 582 consecutive attendees at an outpatient clinic for people with chronic liver disease, a single blood sample was taken for analysis of 'total' AFP and the 'hepatoma-specific' AFP isoform. Using ultrasonography as the primary screening method, patients with AFP levels > or = 50 ng ml-1 were followed up throughout the study or until HCC was diagnosed on the basis of conventionally defined criteria. On entry into the study, 53 patients had an AFP concentration > = or 50 ng ml-1 and the 'hepatoma-specific' AFP isoform was detected in 26 of these. During an 18-month follow-up period, a diagnosis of HCC was established by conventional methods in 19 (17 'definite' and two 'probable') of these 26 patients. In only two cases was there ultrasound evidence of tumour development at the time AFP was first found to be elevated; in the remainder a diagnosis of HCC, based on ultrasound screening, was established at a median time of 3.6 months (range 1-18 months) after entry into the study. Among those 27 without the 'hepatoma-specific' isoform, one developed a 'definite' HCC and two developed 'probable' tumours. With the application of 'hepatoma-specific' AFP, the positive predictive value of the test was 73.1%, compared with only 41.5% using the conventional 'total' AFP test. Application of this test for the 'hepatoma-specific' AFP markedly increases the positive predictive value of AFP and, in some cases, permits the presence of tumour to be inferred before it could be detected by routine ultrasound examination.
机译:有效治疗肝细胞癌(HCC或“肝癌”)的唯一希望在于早期诊断。血清甲胎蛋白(AFP)水平的测量可能是有用的筛选测试。大体上升高时,几乎可以诊断出肝癌。但是,在良性慢性肝病患者中也可能出现适度升高的水平,这显着降低了测试的特异性,因此降低了其临床价值。在582位连续诊治慢性肝病患者的门诊患者中,采集了一次血液样本以分析“总” AFP和“肝癌特异性” AFP亚型。使用超声作为主要的筛查方法,在整个研究过程中随访AFP水平>或= 50 ng ml-1的患者,或者直到根据传统定义的标准诊断出HCC。进入研究后,有53例患者的AFP浓度> =或50 ng ml-1,其中26例检测到“肝癌特异性” AFP亚型。在18个月的随访期内,通过常规方法对这26例患者中的19例(17例“确定”和2例“可能”)进行了HCC诊断。仅在两个案例中,在首次发现AFP升高时,有超声显示肿瘤发展。在其余研究中,基于超声筛查的HCC诊断在进入研究后的中位时间为3.6个月(1-18个月)。在没有“肝癌特异性”同工型的27例中,有1例发展为“确定的” HCC,有2例发展为“可能的”肿瘤。使用“肝癌特异性” AFP时,该测试的阳性预测值为73.1%,而使用常规“总” AFP测试仅为41.5%。在“肝癌特异性” AFP上应用该检测显着提高了AFP的阳性预测价值,在某些情况下,可以在常规超声检查可以发现肿瘤之前就推断出肿瘤的存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号